| Literature DB >> 29724051 |
Abstract
This review presents a detailed analysis of published research data focused on the pharmacological activity exerted by biologically active compounds isolated from sea cucumbers belonging to the class of Holothuroidea, phylum Echinodermata. The review contains descriptions of the structure, physico-chemical properties and pharmacological effects of these active substances. Particular attention is given to compounds with anticoagulant, antithrombotic, antioxidant, anticancer, anti-infectious, immune-stimulating and anti-ACE (angiotensin converting enzyme) activities as well as to the substances exerting a regulating influence on lipid and carbohydrate metabolism. All these compounds may be considered as prototypes for development of new pharmaceutical substances and medicines.Entities:
Keywords: Echinodermata; Holothuroidea; ceramides; fucosylated chondroitin sulfate; glycans; polysaccharides; saponins; sea cucumber; triterpene glycosides
Mesh:
Substances:
Year: 2018 PMID: 29724051 PMCID: PMC5983632 DOI: 10.3390/ijms19051342
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Taxonomy of sea cucumbers containing bioactive compounds with experimentally confirmed pharmacological activity (Holothurian classification is presented in accordance with World Register of Marine Species).
| Species * | Bioactive Compounds |
|---|---|
| Order Dendrochirotida | |
| Triterpene glycoside: colochiroside A | |
|
| Polysaccharides: fucosylated chondroitin sulfate; Triterpene glycosides: frondosides A, A1, A6, 24-dehydrofrondoside A6; |
| Triterpene glycosides: cucumariosides A2-2, A4-2 | |
| Triterpene glycosides: pentactasides I, II, III, philinopsides A, B, E, | |
|
| Triterpene glycosides: violaceusides A, B |
|
| Triterpene glycoside: intercedensides A, B, C |
|
| |
|
| Polysaccharides: fucosylated chondroitin sulfate |
|
| |
|
| Triterpene glycoside: patagonicoside A |
|
| |
|
| Polysaccharides: fucosylated chondroitin sulfate; |
|
| |
|
| Holothurin A |
|
| Ethanol extract |
|
| Peptide hydrolysates, Triterpenes Holothurin A, B, methanol extract |
|
| Ethanol extract |
|
| Triterpene glycosides: argusides A, B, C, D, E; Galactocerebroside |
|
| Triterpene glycosides: marmoratoside A, impatienside A, 17α-hydroxy impatienside A, bivittoside D |
|
| Phenolic compounds |
|
| Polyunsaturated fatty acids: arachidonic, eicosapentaenoic, docosahexaenoic acids; |
|
| Phospholipids: lysoplatelet activating factor, lysophosphatidylcholine, ethanol extract |
|
| Polysaccharides: sulfated fucan, fucosylated chondroitin sulfate |
|
| Polysaccharides: fucosylated chondroitin sulfate |
|
| Triterpene glycosides: fuscocinerosides A, B, C |
|
| Triterpene glycosides: 17-dehydroxyholothurinoside A, griseaside A |
|
| Triterpene glycoside: hillaside C |
|
| Triterpene glycosides: impatienside A, 17α-hydroxyimpatienside A |
|
| Polysaccharides: glycosaminoglycan; |
|
| Polysaccharides: fucosylated chondroitin sulfate |
|
| Triterpene glycosides: moebioside A, holothurin A, holothurin B, 24-dehydroechinoside B |
|
| Polysaccharides: sulfated fucan, fucosylated chondroitin sulfate |
|
| Triterpene glycosides: scabrasides B, D, echinoside A, 24-dehydroechinoside A, HS-1, holothurins A, A1, A3, A4, B, B4, fuscocineroside C |
|
| Saponin complex |
|
| Triterpene glycosides: echinoside A, Ds-echinoside A, 24-dehydroechinoside A, holothurin A; |
|
| |
|
| Polysaccharide: fucosylated chondroitin sulfate; |
|
| |
|
| Polysaccharides: sulfated fucan, fucosylated chondroitin sulfate; |
|
| Polysaccharides: fucosylated chondroitin sulfate, sulfated fucan; |
|
| Triterpene diglycosides: stichorrenosides A, B, C, D, stichoposides A, B, 3β- |
|
| Collagen hydrolysates |
|
| Polysaccharides: fucosylated chondroitin sulfate |
|
| Triterpene glycosides: stichoposide C, cucumarioside A2-2, cucumarioside A4-2 |
* Taxons in parentheses are synonyms.
Figure 1The basic backbone structure of 1-3-linked fucose residues in many sulfated fucans from marine organisms. R may be hydrogen, sulfate, or a galactose or fucose side chain.
Figure 2Preponderant structure of the fucosylated chondroitin sulfate. The backbone is made up by repeating disaccharide units of alternating β-d-glucuronic acid (A) and N-acetyl-β-d-glucosamine (B). The β-d-glucuronic acid residues bear 2,4-disulfated fucose branches (C) at the 3-O-position. R may be hydrogen or sulfate.
Figure 3Neutral glucan from sea cucumber Holothuria edulis. The major component of polysaccharide is an α-(1→4)-d-glucan branched with a single α-d-glucose at C-6 every five residues on average.
Figure 4Structures of lanostane, holostane and holostanol. A, B, C, D, E: rings of the pentacyclic triterpene.
Comparative chemical composition and average molecular weight of sea cucumber polysaccharides.
| Sample | Source | Chemical Composition (Molar Ratios) | Mn | MW | MW/Mn | Reference | |||
|---|---|---|---|---|---|---|---|---|---|
| GlcA | GalNAc | Fuc | Glc | ||||||
| Sulfated fucan |
| <0.01 | <0.01 | 1.00 | <0.01 | 517.90 | 615.50 | 1.19 | [ |
| Sulfated fucan |
| <0.01 | <0.01 | 1.00 | <0.01 | 225.90 | 419.90 | 1.86 | |
| Sulfated fucan |
| <0.01 | <0.01 | 1.00 | <0.01 | 289.40 | 475.80 | 1.64 | |
| Fucosylated chondroitin sulfate |
| 1 | 1.28 | 0.82 | <0.01 | 41.34 | 51.09 | 1.24 | |
| Fucosylated chondroitin sulfate |
| 1 | 1.05 | 1.03 | <0.01 | 46.76 | 56.82 | 1.22 | |
| Fucosylated chondroitin sulfate |
| 1 | 0.96 | 0.82 | <0.01 | 42.46 | 55.32 | 1.30 | |
| Neutral glucan |
| <0.01 | <0.01 | <0.01 | 1.00 | 197.90 | 253.30 | 1.28 | |
| Heparin (commercial drug) | Porcine intestine | ND | ND | ND | <0.01 | 20.23 | 26.26 | 1.30 | |
| Neutral glucan |
| <0.01 | <0.01 | <0.01 | 1.00 | 197.90 | 253.30 | 1.28 | |
| Fucosylated chondroitin sulfate |
| 1.43 | 1 | 1.71 | ND | 94.78 | 109 | 1.15 | [ |
| Depolymerized fucosylated chondroitin sulfate | 1.35 | 1 | 1.70 | ND | 4.60 | 7.4 | 1.61 | ||
| Depolymerized fucosylated chondroitin sulfate | 1.32 | 1 | 1.72 | ND | 2.89 | 5.2 | 1.80 | ||
| Depolymerized fucosylated chondroitin sulfate | 1.30 | 1 | 1.71 | ND | 2.38 | 4.3 | 1.80 | ||
| Low molecular weight heparin (commercial drug) | Porcine intestine | 5.0 | 6.4 | 1.28 | |||||
GlcA: glucuronic acid; GalNAc: N-acetyl-β-d-galactosamin; Fuc: α-l-Fucose; Glc: d-glucose; Mn: number-average molecular mass; MW: weight-average molecular mass; MW/Mn: molecular weight distribution; ND: not determined.
Comparative anticoagulant activities o sea cucumber polysaccharides and heparins.
| Sample | Source | MW | APTT | TT | TP | Reference |
|---|---|---|---|---|---|---|
| Sulfated fucan |
| 615.50 | 13 | <1 | <1 | [ |
| Sulfated fucan |
| 419.90 | 19 | <1 | <1 | |
| Sulfated fucan |
| 475.80 | 9 | <1 | <1 | |
| Fucosylated chondroitin sulfate |
| 51.09 | 89 | 6 | <1 | |
| Fucosylated chondroitin sulfate |
| 56.82 | 116 | 7 | <1 | |
| Fucosylated chondroitin sulfate |
| 55.32 | 59 | 4 | <1 | |
| Neutral glucan |
| 253.30 | <1 | <1 | <1 | |
| Heparin | Porcine intestine (commercial drug) | 26.26 | 212 | 212 | 212 | |
| Sulfated fucan |
| 450 | 9 | 6 | [ | |
| Fucosylated chondroitin sulfate |
| Not specified | 183 | 157 | ||
| Heparin | Porcine intestine (commercial drug) | 150 | 150 | |||
| Fucosylated chondroitin sulfate |
| 109 | 187 | 157 | [ | |
| Depolymerized fucosylated chondroitin sulfate * |
| 7.4 | 103.8 | 34.3 | ||
| Depolymerized fucosylated chondroitin sulfate * |
| 5.2 | 60.5 | <1 | ||
| Depolymerized fucosylated chondroitin sulfate * |
| 4.3 | 34.8 | <1 | ||
| Low molecular weight heparin | Porcine intestine (commercial drug) | 6.4 | 69 | 64 | ||
| Heparin | Porcine intestine (commercial drug) | 18.6 | 212 | 212 |
MW: molecular weight; APTT: activated partial thromboplastin time; TT: thrombin time; PT: prothrombin time. The anticoagulant activity is expressed as USP (United States Pharmacopeia) units/mg (IU/mg) using a parallel standard curve based on the International Heparin Standard (212 or 150 IU/mg). * The depolymerized fucosylated chondroitin sulfate samples were prepared using modified free-radical depolymerization induced by Cu2+ catalyzed Fenton system.
Comparative in vitro antithrombotic activities of sea cucumber polysaccharides and heparins.
| Thrombogenesis in the Artificial Blood Vessel | ||||||
|---|---|---|---|---|---|---|
| Sample | Source | MW | Length of Thrombus | Weight of Thrombus | Reference | |
| Normal blood | 2.16 ± 0.52 | 110.47 ± 9.49 | [ | |||
| Sulfated fucan (0.5 mg/mL) |
| 450 | 2.02 ± 0.24 | 40.58 ± 8.05 a | ||
| Sulfated fucan (1.0 mg/mL) | 2.05 ± 0.26 | 35.08 ± 5.10 a | ||||
| Fucosylated chondroitin sulfate (0.3 mg/mL) | Not specified | 1.80 ± 0.33 | 35.40 ± 7.15 a | |||
| Fucosylated chondroitin sulfate (0.5 mg/mL) | 1.73 ± 0.42 | 32.73 ± 5.35 a | ||||
| Heparin (Jiangsu Pharmacia, China) (0.3 mg/mL) | ND | ND | ||||
|
| ||||||
|
|
|
| ||||
|
| [ | |||||
| Native fucosylated chondroitin sulfate |
| 120–140 | 0.40 | 0.56 | 120 | |
| Depolymerized fucosylated chondroitin sulfate | 6 | 0.46 | <limit of detection | 7.8 | ||
| Depolymerized fucosylated chondroitin sulfate | 2.5 | 0.181 | <limit of detection | 0.65 | ||
| Heparin | 203 | 196 | 206 | |||
|
| [ | |||||
| Sulfated fucan |
| 616 | >1000 | 78.7 ± 6.2 | 0.7 ± 0.02 | |
| Sulfated fucan |
| 564 | >1500 | 66.5 ± 11 | 0.5 ± 0.03 | |
| Heparin | 0.03 ± 0.003 | 0.015 ± 0.001 | 0.2 ± 0.01 | |||
|
| [ | |||||
| Sulfated fucan |
| 450 | 0.53 | 0.32 | 2.55 | |
| Fucosylatedchondroitin sulfate | Not specified | 2.58 | 0.56 | 0.05 | ||
| Heparin | 0.005 | 0.01 | 0.98 | |||
ND: thrombus not detected; HCII: heparin cofactor II; IU: international unit; IC50: half maximal inhibitory concentration; * samples were tested against the 6th International Standard for unfractionated heparin (07/328); ** samples were tested against the 2nd International Standard for low molecular weight heparin (01/608). a p < 0.05, compared with normal blood.
Figure 5Common sugar units present in sea cucumber triterpene glycosides [59].
Figure 6Some common carbohydrate architectures in the sea cucumber triterpene glycosides. The sugar moieties are 3-O-methyl-d-glucose (MeGlc), d-glucose (Glc), d-xylose (Xyl), d-quinovose (Qui), 3-O-methyl-d-xylose (MeXyl) [59].
Cytotoxic effects of sea cucumber triterpene glycosides against various tumor cells.
| Compounds | Type of Tumor Cell Lines | Activity Result, IC50 | Reference |
|---|---|---|---|
| Arguside A | Human leukemia HL-60, human colon cancer HCT-116, human hepatocellular carcinoma BEL-7402, human stomach adenocarcinoma MKN45 | 0.14–4.42 μM | [ |
| Arguside B | Human lung cancer A549, HCT-116, human hepatocellular carcinoma human breast cancer MCF-7 | 0.46–2.60 μg/mL | [ |
| Arguside C | A549, HCT-116, HepG2, MCF-7 | 0.38–2.56 μg/mL | [ |
| Arguside D | A549, HCT-116, HepG2, MCF-7 | 3.45–7.77 μg/mL | [ |
| Arguside E | A549, HCT-116, HepG2, MCF-7 | 3.36–7.53 μg/mL | [ |
| Bivittoside D | Colon carcinoma HT-29, HCT-116, human prostate cancer DU-145, MCF-7, human epidermoid carcinoma KB, A549, HepG2 | 0.37–2.46 μg/mL | [ |
| Colochiroside A | Murine leukemia P-388, HL-60, A549, lung adenocarcinoma SPC-A4, stomach adenocarcinoma MKN28, gastric carcinoma SGC-7901 | 3.61 ± 0.55 μg/mL | [ |
| Cucumarioside A2-2 | HL-60, human leukemia THP-1, human leukemia NB-4, human leukemia K562 | Effective concentration: ≥5 μM | [ |
| Cucumarioside A4-2 | HL-60, THP-1, NB-4, human leukemia K562 | Effective concentration: ≥5 μM | [ |
| Echinoside A | Human cervical cancer HeLa, HepG2, K562 | 1.25–1.61 μg/mL | [ |
| HepG2 | 2.70 μmol/L | [ | |
| Ds-echinoside A | HepG2, | 2.65 μmol/L | [ |
| 24-Dehydroechinoside A | HepG2 | 3.14 μM | [ |
| HeLa, HepG2, K562 | 1.95–6.15 μg/mL | [ | |
| 24-Dehydroechinoside B | Rat glioma C6, human glioma U-87-MG, human glioma U251, human glioma SHG-44 | 1.99–6.10 μM | [ |
| Frondoside A | Human pancreatic cancer AsPC-1 | Effective concentration: 4 μg/mL | [ |
| Human lung cancer LNM35, A549, human lung carcinoma NCI-H460-Luc2, human melanoma MDA-MB-435, human mammary adenocarcinoma MCF-7, HepG2 | 1.7–2.5 μM | [ | |
| A549 | 0.6 μM | [ | |
| HeLa, HepG2, K562 | 3.30–4.14 μg/mL | [ | |
| Frondoside A1 | HeLa, HepG2, K562 | 1.91–2.21 μg/mL | [ |
| Fuscocineroside A | HL-60, BEL-7402 | 0.58–0.88 μg/mL | [ |
| Fuscocineroside B | HL-60, BEL-7402 | 0.58–0.88 μg/mL | [ |
| Fuscocineroside C | HL-60, BEL-7402 | 0.58–0.88 μg/mL | [ |
| Griseaside A | A549, HL-60, BEL-7402, human acute lymphoblastic leukemia Molt-4 | 0.427–2.60 μM | [ |
| Hillaside C | A549, MCF-7, human lung carcinoma IA9, human clear cell carcinoma CAKI-1, human prostate adenocarcinoma PC-3, KB, nasopharyngeal cancer KB-VIN, HCT-8 | 0.15–3.20 μg/mL | [ |
| Holothurin A | HL-60, BEL-7402 | 0.58–0.88 μg/mL | [ |
| HeLa, HepG2, K562 | 3.46–8.94 μg/mL | [ | |
| C6, U87-MG, U251, SHG-44 | 0.99–4.03 μM | [ | |
| Holothurin A1 | HepG2, | 3.40 μM | [ |
| Holothurin A1 | HeLa, HepG2, K562 | 2.84–6.50 μg/mL | [ |
| Holothurin A3 | KB, HepG2 | 0.32–0.87 μg/mL | [ |
| Holothurin A4 | KB, HepG2 | 0.57–1,12 μg/mL | [ |
| Holothurin B | HeLa, HepG2, K562 | 1.79–3.64 μg/mL | [ |
| Holothurins B | C6, U87-MG, U251, SHG-44 | 1.39–8.64 μM | [ |
| Holothurin B4 | HeLa, HepG2, K562 | 2.71–3.55 μg/mL | [ |
| Dehydroxyholothurinoside A | A549, HL-60, BEL-7402, Molt-4 | 0.245–0.97 μM | [ |
| Impatienside A | HT-29, HCT-116, DU-145, MCF-7, KB, A549, HepG2 | 0.353–2.72 μg/mL | [ |
| Intercedensides A, B, C | A549, MCF-7, IA9, CAKI-1, U-87-MG, PC-3, KB, KB-VIN, human skin melanoma SK-MEL-2, HCT-8 | 0.60–4.00 μg/mL | [ |
| Moebioside A | C6, U87-MG, U251, SHG-44 | 1.22–4.39 μM | [ |
| Patagonicoside A | Human hepatocarcinoma Hep3B, breast cancer MDA-MB-231, A549 | 0~80 μM | [ |
| Pervicoside C | HCT-116 and A549 | 18.7–28.6 μg/mL | [ |
| Pentactasides I, II, III | P-388, A549, MCF-7, MKN28, HCT-116, U87-MG | 0.60–3.95 μM | [ |
| Philinopside A | P-388, A549, MCF-7, MKN28, HCT-116, U87MG | 0.60–3.95 μM | [ |
| BEL-7402, MCF-7, ovarian epitheloid carcinoma HO-8910, mouse Sarcoma-180 | 1.5–2.4 μM | [ | |
| Philinopside B | P-388, A549, MCF-7, MKN28, HCT-116, U87MG | 0.60–3.95 μM | [ |
| Philinopside E | MKN28, P-388, BEL-7402, HL-60, SPC-A4, A549, SGC7901, human ovarian carcinoma HO8901, human fetal lung fibroblasts W138, human epithelial carcinoma A431 | 0.75–3.50 μg/mL | [ |
| BEL-7402, SPC-A4, ovarian epitheloid carcinoma HO-8910 | 2.4–4.1 μM | [ | |
| Scabraside B | HeLa, HepG2, K562 | 4.44–11.85 μg/mL | [ |
| Stichoposide C | HL-60, K562, NB-4, THP-1, colorectal cancer CT-26, HT-29, colon adenocercinoma SNU-C4 | Effective concentrations: | [ |
| Scabraside D | HeLa, HepG2, K562 | 3.33–10.06 μg/mL | [ |
| Stichorrenosides A, B, C, D | KB, HepG2, MCF-7, human prostate adenocarcinoma LNCaP cells, SK-Mel-2 | 1.31–3.53 μM | [ |
| Violaceusides I, II, III | MKN45, HCT-116 | 0.068–0.352 μM | [ |
Figure 7Representative structure of glucosylceramide (d-glucosyl-β-1,1′-N-palmitoylsphingosine).
Figure 8Structures of naturally occurring sphingoid bases.
Cytotoxicity of sea cucumber cerebrosides against cancer cells.
| Compounds | Source | Type of Tumor Cell Lines | Pharmacological Effect, Anticancer Mechanism | Reference |
|---|---|---|---|---|
| Sphingoid bases |
| Human colon cancer cells Caco-2, DLD-1 and WiDr | Reduction of cell viability, induction of apoptosis, increasing caspase-3 activity | [ |
| Glucocerebrosides, sphingoid bases |
| Caco-2 | Inhibition of cell proliferation | [ |
| Glucocerebrosides |
| Murine sarcoma cells S180 | Induction of apoptosis | [ |
| Sphingoid bases | Species not specified | Human hepatoma cells Hep-G2 | Reduction of cell viability, induction of apoptosis, upregulation of death receptor-5, apoptosis inducer protein Bax, growth arrest and DNA-damage-inducible protein DNA-damage-inducible gene 45 and peroxisome proliferator-activated receptor-γ, downregulation of protein kinase p-AKT, increasing of caspase-3 and caspase-8 activities | [ |
Antiprotozoal, antifungal and antiviral activities of sea cucumber bioactive compounds.
| Compounds | Source | Targets | Reference |
|---|---|---|---|
| Fucosylated chondroitin sulfate |
|
| [ |
| Fucosylated chondroitin sulfate |
|
| [ |
| Holothurin B |
|
| [ |
| Holothurin B |
|
| [ |
| Marmoratoside A, bivittoside D, impatienside A, 17α-hydroxy impatienside |
| [ | |
| Holotoxins B, A, A1 |
| [ | |
| Fucosylated chondroitin sulfate |
| Human immunodeficiency virus (HIV) | [ |